A prognostic Alzheimer’s disease blood test in the symptom-free stage
December 2020
Ruhr University Bochum, Bochum, Germany
The authors evaluated amyloid-beta misfolding as a prognostic tool for future clinical progression to mild cognitive impairment or dementia due to Alzheimer’s disease (AD) in 203 individuals with subjective cognitive decline over the course of 6 years. The results suggest that a panel of structure- and concentration-based plasma amyloid biomarkers may predict conversion to clinical mild cognitive impairment and dementia due to AD in cognitively unimpaired subjects. These plasma biomarkers provide a noninvasive and cost-effective alternative for screening early AD pathological changes.
Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
Klaus Gerwert
Added on: 01-29-2021
[1] https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00738-8[2] https://www.bionity.com/en/news/1169324/a-prognostic-alzheimers-disease-blood-test-in-the-symptom-free-stage.html
